Liver Transplantation Pathology

  • Maura O’Neil
  • Ivan Damjanov
  • Ryan M. Taylor
Part of the Pathology for Clinicians book series (PACLIN)


Liver transplantion is the treatment for end stage chronic liver diasese, acute liver failure with massive liver necrosis, malignant liver tumors, and chronic metabolic or genetic diseases. The interpretation of liver biopsies to evaluate the donor liver as well as the changes that occur after transplant requires specialized knowledge related to liver transplantation such as the following: graft preservation/reperfusion injury, vascular and biliary tract injuries, cell mediated and antibody mediated rejection, complications of immunosuppression, and recurrence of original liver disease.


Bile Duct Portal Tract Acute Cellular Rejection Hepatic Artery Thrombosis Donation After Cardiac Death 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Demetris AJ, Crawford JM, Isse K, et al. Pathology of liver and hematopoietic stem cell transplantation. In: Odze RD, Goldblum JR, editors. Surgical pathology of the GI tract, liver, biliary tract, and pancreas. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1408–61.Google Scholar
  2. Hübscher SG, Clouston AD. Transplantation pathology. In: Burt AD, Portman BC, Ferrell LD, editors. MacSween’s pathology of the liver. 6th ed. Edinburgh: Elsevier Churchill Livingstone; 2012. p. 853–933.CrossRefGoogle Scholar
  3. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris N, editors. WHO classification of lymphoproliferative disorders. Lyons: IARC Press; 2008. p. 343–6.Google Scholar
  4. Torbenson M. Biopsy interpretation of the liver. Philadelphia, PA: Wolters Kluwer Health; 2015.Google Scholar
  5. Xiao S-Y, Oshima K. Liver pathology. New York, NY: Demos Medical; 2015.Google Scholar
  6. Bardou-Jacquet E, Philip J, Lorho R, et al. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. Hepatology. 2014;59:839–47.CrossRefPubMedGoogle Scholar
  7. Kerkar N, Morotti RA, Madan RP, et al. The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant. 2010;14:504–11.CrossRefPubMedGoogle Scholar
  8. Kim H, Lee K, Lee KW, et al. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant. 2014;28:521–9.CrossRefPubMedGoogle Scholar
  9. Lo RC, Chan SC, Chan KL, et al. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study. J Clin Pathol. 2013;66:392–8.CrossRefPubMedGoogle Scholar
  10. Patil DT, Yerian LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. Liver Transpl. 2012;18:1147–53.CrossRefPubMedGoogle Scholar
  11. Piselli P, Busnach G, Fratino L, et al. Immunosuppression and Cancer Study Group. De novo malignancies after organ transplantation: focus on viral infections. Curr Mol Med. 2013;13:1217–27.CrossRefPubMedGoogle Scholar
  12. Said A. Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances. World J Gastroenterol. 2013;19:9146–55.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Maura O’Neil
    • 1
  • Ivan Damjanov
    • 1
  • Ryan M. Taylor
    • 2
  1. 1.University of Kansas School of MedicineUniversity of KansasKansas CityUSA
  2. 2.Division of Gastroenterology and HepatologyUniversity of Kansas School of MedicineKansas CityUSA

Personalised recommendations